Y90-Ibritumomab tiuxetan (Y90-IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05)
| Autor: | Erika Lerch, Michele Ghielmini, Jochen Rentschler, Thomas Pabst, Lorenz M. Jost, Stephanie Rondeau, Simona Berardi Vilei, Mario Bargetzi, Luciano Wannesson, Angelika Bischof Delaloye, Michèle Voegeli, Nicolas Ketterer |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Melphalan
Cancer Research medicine.medical_specialty medicine.medical_treatment Ibritumomab tiuxetan Gastroenterology 03 medical and health sciences 0302 clinical medicine Autologous stem-cell transplantation Internal medicine medicine Mucositis Chemotherapy business.industry Hematology General Medicine medicine.disease Surgery Transplantation Oncology 030220 oncology & carcinogenesis business Progressive disease Febrile neutropenia 030215 immunology medicine.drug |
| Zdroj: | Hematological Oncology. 35:576-583 |
| ISSN: | 0278-0232 |
| Popis: | Standard conditioning regimens for autologous stem cell transplantation (ASCT) are often not tolerated by elderly patients, on one hand. Single high-dose melphalan, on the other hand, has been shown to be safe and active as a pretransplant preparative regimen in elderly patients. Y90 -Ibritumomab tiuxetan (Y90 -IT) is well tolerated and feasible in the transplantation setting. We therefore investigated the combination of high-dose melphalan and Y90 -IT as a conditioning regimen for patients ≥65 years of age. Patients with relapsed or resistant CD20-positive lymphoma in remission after salvage chemotherapy could be enrolled. High-dose therapy consisted of standard dose Y90 -IT (0.4-mCi/kg body weight) followed by melphalan at escalating doses (100, 140, 170 and 200 mg/m2 ) and ASCT. The primary objective was to identify the maximum tolerated dose; secondary end points were complete response (CR) rate 100 days after transplantation and toxicity. Twenty patients (median age 72 years) were included. No DLT occurred at any dose level. Thirteen patients completed the treatment, 11 were evaluable for response. Seven patients did not complete treatment because of mobilization failure (n = 3), progressive disease (n = 2), worsening of cardiac function (n = 1), and grade 3 dyspnea (n = 1). Seven patients achieved a CR/complete remission/unconfirmed (CRu) and 2 had stable disease. Five out of 7 responding patients were still alive more than 3 years after transplantation. The 2 patients with SD had a long-term survival of 3 and 5 years, respectively. Nonhematological grade 3 or higher treatment related adverse events (AEs) were infection (n = 6), including 2 cases of febrile neutropenia, diarrhea (n = 3), mucositis, anorexia, viral hepatitis, hypokalemia, dehydration, and multiorgan failure (n = 1 for each). The combination of Y90 -IT and high-dose melphalan is feasible before ASCT for elderly patients, with promising activity and manageable toxicity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text